Novel high-risk subtypes in adult B-ALL, Liso-cel CAR-T therapy in CLL, and liquid biopsies in large B-cell lymphomas

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Booked out doesn't mean you're ready for an associate OD 23 min · 23 Sep 2026 · The Optometry Success Podcast

Could sofa theory help you find your ideal partner? 4 min · 23 Sep 2026 · Do you really know?

Behind The Scenes At Vogue World Milano 28 min · 23 Sep 2026 · The Run-Through with Vogue

Is end-to-end encryption really secure? 4 min · 23 Sep 2026 · Do you really know?

Do tongue scrapers actually help with bad breath? 5 min · 23 Sep 2026 · Do you really know?

Lab Notes: Have we found dark matter? 10 min · 23 Sep 2026 · The Science Show

Report any issue

Source

Recorded24 Mar 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742094

Show notes

In this week's podcast, we’ll cover a research article that describes two novel subgroups of adult B-cell ALL with high expression of CDX2 and IDH mutations that are linked to poor prognosis. Next, we'll cover results from TRANSCEND CLL 004, a phase 1 study of the CAR T cell therapy, liso-cel, in patients with relapsed or refractory CLL. We will close with research that provides new insights into how analysis of circulating tumor DNA could inform management of patients with aggressive B-cell lymphomas.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in